Core Viewpoint - Zhongheng Group has acquired a patented technology for a new drug to treat chronic heart failure, indicating a strategic move to enhance its product line and market competitiveness [1] Group 1: Acquisition Details - Zhongheng Group's subsidiary, Zhongheng Innovation, has purchased a drug technology for chronic heart failure for RMB 55 million [1] - The acquired drug is a Class 1 innovative chemical drug that addresses energy metabolism disorders in myocardial cells, offering a new treatment pathway [1] - There are currently no similar mechanism products available in the domestic and international markets [1] Group 2: Strategic Implications - The acquisition aligns with Zhongheng Group's strategic focus on unmet clinical needs and potential markets, particularly in cardiovascular, metabolic, and autoimmune diseases [1] - The company aims to enhance its business and product line through this acquisition, thereby increasing its market competitiveness [1] - Zhongheng Group is building a differentiated competitive advantage in cardiovascular treatment by leveraging a dual-driven model of independent R&D and strategic acquisitions [1]